
Healthcare Global Enterprises Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Q1 FY25 revenue at an all-time high of Rs. 526 crore, reflecting 17% growth YoY (adjusted for discontinued centers).
- Established centers, excluding fertility business, grew 18% YoY with strong volume growth and improved realization.
- Early Q2 performance strong, expected 14-15% growth QoQ, led by operational leverage.
- Anticipated ongoing 13-15% revenue growth in existing hospitals for full year.
- International business doubled compared to pre-COVID levels; focus on expanding markets in SAARC, Middle East, and Africa.
- Acquisition of MG Hospital (Vizag) expected to boost consolidated revenue, expanding market share to 46% in region with 10-12% expected growth.
- Emerging centers growing rapidly at 33% YoY; established centers growing at 14% YoY.
- Improvements in Average Length of Stay (ALOS) and ARPOB (up 12% YoY) supporting volume and revenue expansion.
- Expansion through Brownfield and new facilities, with CAPEX around Rs. 80 crores per quarter to support growth.
See what Healthcare Global Enterprises management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Post-acquisition of Vizag, the company's debt will initially increase by Rs. 200 crores and later by another Rs. 150 crores after 18 months to complete an 85% acquisition.
- The management plans to seek board approval at the appropriate time for a primary equity raise ("primary"), aimed at significantly reducing debt.
- The exact size of the primary equity raise will be communicated when finalized.
- The company intends to maintain its debt-to-equity ratio within internally accepted ranges, targeting a debt-to-EBITDA ratio of around 2.5x to 2.75x on a pre-Ind AS basis.
- Currently, there are no mature inorganic acquisition opportunities under evaluation, but the company continues to assess strategic inorganic options.
- CAPEX funding partly involves debt; Rs. 50 crores of the Rs. 80 crores CAPEX in Q1 was funded through debt, contributing to increased finance costs.
- Overall, a primary equity raise is planned in the medium term to manage leverage following recent acquisitions.
See what Healthcare Global Enterprises management said on order book — free account, 30 seconds.
Capex plans
Yes- Current quarter CAPEX was about Rs. 80 crores.
- CAPEX for the rest of the year is expected to remain in a similar range (around Rs. 80 crores per quarter).
- Investments are focused on Brownfield facilities and new facilities like Whitefield and North Bangalore.
- Additional ROU of Rs. 200 crores related to new facilities in Ahmedabad and North Bangalore added.
- Post-acquisition of Vizag-based Mahatma Gandhi Hospital, no immediate additional equipment CAPEX planned, as the hospital is well-equipped (robotic unit, PET scan, linear accelerators).
- A new linear accelerator is being added to the Vizag center as part of the CAPEX.
- Company aims to optimize operational efficiencies and synergies across hospitals to drive growth and cost management.
Track Healthcare Global Enterprises — get its next earnings analysis in your feed
How does Healthcare Global Enterprises rank vs peers in Healthcare Services?
Pro featureHow does Healthcare Global Enterprises rank in Healthcare Services?
Compare Healthcare Global Enterprises against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Healthcare Global Enterprises's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.